Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
Advertisement

Related Content

FDA Starts Process For Regulating Next-generation Vaccine Adjuvants
FDA Starts Process For Regulating Next-generation Vaccine Adjuvants
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
GSK Will Answer FDA “Complete Response” Letter For Cervarix In Second Quarter
GSK Receives “Complete Response” Letter For Cervarix BLA
Anadys Resumes Work With TLR7 Drug
Anadys Resumes Work With TLR7 Drug
GlaxoSmithKline Submits Cervarix BLA
GlaxoSmithKline Submits Cervarix BLA

Topics

Advertisement
UsernamePublicRestriction

Register

PS068012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel